June 09, 2017
Wilson Therapeutics Receives US Orphan Drug Designation for WTX101 for the Treatment of ALS
Media
June 08, 2017
TARGOVAX ASA – SUCCESSFULLY COMPLETED PRIVATE PLACEMENT
June 08, 2017
Wilson Therapeutics presents Phase 2 data for WTX101 at MDS meeting
June 07, 2017
Accepted abstract by ICML with updated results from Phase 1/2 trial of Betalutin® in NHL is now available on-line
June 07, 2017
Positive results from the CER-209 Phase I Single Dose Tolerance study for NAFLD and NASH
June 06, 2017
Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
June 02, 2017
Nordic Nanovector to Present at Jefferies Healthcare Conference in New York on Thursday June 8th
June 02, 2017
Orexo receives USD 2.5 million milestone payment from AstraZeneca as OX-CLI advances into clinical trials
May 24, 2017
Nordic Nanovector ASA – Results for First Quarter 2017
May 23, 2017
Onxeo Announces 10th Positive DSMB Recommendation to Continue Livatag® ReLive Phase III Trial in HCC